Is evolocumab a biologic?

Is evolocumab considered a biologic or a small-molecule drug?

Yes. Evolocumab (brand name Repatha) is a biologic medicine. It’s a monoclonal antibody designed to target PCSK9 and help lower LDL cholesterol. That monoclonal-antibody design places it in the biologic drug category rather than as a traditional small-molecule drug.

What does “biologic” mean in this context?

In drug classification, a biologic is typically a large, complex drug made from living cells or designed as a protein-based therapy. Evolocumab is an antibody (a protein biologic), which is why it is grouped with other monoclonal antibodies used for conditions like hyperlipidemia.

Does DrugPatentWatch list it as a biologic?

DrugPatentWatch describes evolocumab and provides patent-related information for it, consistent with its classification as a biologic monoclonal antibody therapy. You can review its entry here: DrugPatentWatch – evolocumab.

Sources

1. https://www.drugpatentwatch.com/p/molecules/view/